5‐HT4receptor agonists: similar but not the same
Authors:
- 10 January 2008
- journal article
- review article
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 20 (2) , 99-112
Abstract
Abstract 5‐Hydroxytryptamine4(5‐HT4) receptors are an interesting target for the management of patients in need of gastrointestinal (GI) promotility treatment. They have proven therapeutic potential to treat patients with GI motility disorders. Lack of selectivity for the 5‐HT4receptor has limited the clinical success of the agonists used until now. For instance, next to their affinity for 5‐HT4receptors, both cisapride and tegaserod have appreciable affinity for other receptors, channels or transporters [e.g. cisapride: human ether‐a‐go‐go‐related gene (hERG) is K+channel and tegaserod: 5‐HT1and 5‐HT2receptors]. Adverse cardiovascular events observed with these compounds are not 5‐HT4receptor‐related. Recent efforts have led to the discovery of a series of selective 5‐HT4receptor ligands, with prucalopride being the most advanced in clinical development. The selectivity of these new compounds clearly differentiates them from the older generation compounds by minimizing the potential of target‐unrelated side effects. The availability of selective agonists enables the focus to shift to the exploration of 5‐HT4receptor‐related differences between agonists. Based on drug‐ and tissue‐related properties (e.g. differences in receptor binding, receptor density, effectors, coupling efficiency), 5‐HT4receptor agonists are able to express tissue selectivity, i.e. behave as a partial agonist in some and as a full agonist in other tissues. Furthermore, the concept of ligand‐directed signalling offers great opportunities for future drug development by enlarging the scientific basis for the generation of agonist‐specific effects in different cell types, tissues or organs. Selective 5‐HT4receptor agonists might thus prove to be innovative drugs with an attractive safety profile for better treatment of patients suffering from hypomotility disorders.Keywords
This publication has 117 references indexed in Scilit:
- 5-Hydroxytryptamine4Receptor Activation of the Extracellular Signal-regulated Kinase Pathway Depends on Src Activation but Not on G Protein or β-Arrestin SignalingMolecular Biology of the Cell, 2007
- A comparison of the pharmacological properties of guinea‐pig and human recombinant 5‐HT4receptorsBritish Journal of Pharmacology, 2007
- The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI DisordersGastroenterology, 2007
- Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trialBMJ, 2006
- Drugs Acting on Serotonin Receptors for the Treatment of Functional GI DisordersDigestive Diseases, 2006
- Regulation of the amyloid precursor protein ectodomain shedding by the 5‐HT4 receptor and EpacFEBS Letters, 2005
- Characterization of human 5-HT4(d)receptor desensitization in CHO cellsBritish Journal of Pharmacology, 2003
- Ras-dependent ERK Activation by the Human Gs-coupled Serotonin Receptors 5-HT4(b) and 5-HT7(a)Journal of Biological Chemistry, 2003
- Serotoninergic neuroenteric modulatorsThe Lancet, 2001
- The effect of oral cisapride on colonic transitAlimentary Pharmacology & Therapeutics, 1987